The majority of studies on ERCC1 and cisplatin, in NonSmall Cell Lung Cancer (NSCLC) as well as in other solid tumours, share in common the finding that low-ERCC1 expression is associated with a better response to platinum-based chemotherapy [11-13]. The gene discussed is ERCC1; the disease is lung cancer.